Yearly Archives: 2012

Allon Presents Baseline Data from PSP Clinical Trial to Alzheimers Conference

VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) announced that data presented at the Alzheimer’s Association International Conference (AAIC) in Vancouver confirm the integrity of patient enrollment and the importance of cognitive impairment in its pivotal clinical trial evaluating the Compan... Continue reading →

Allon CEO updates Bloom Burton & Co. Healthcare Investor Conference

VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) President and CEO Gordon McCauley is presenting an update of the Company’s progress today at the Bloom Burton & Co. Healthcare Investor Conference at the Toronto Board of Trade in Toronto. McCauley’s presentation will include an update of ... Continue reading →

Allon Therapeutics shareholders approve $10-million private placement

VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) said today that its shareholders have approved the terms of the $10 million brokered private placement equity offering previously announced by the Company May 2. The approval triggers the conversion of the subscription receipts sold as part of ... Continue reading →

Allon CEO updates BioFinance Conference on pivotal trial progress and DSMB recommendation

VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) President and CEO Gordon McCauley is presenting an update of the Company’s progress today at the BioFinance 2012 investor conference in Toronto. McCauley’s presentation will include the latest review of the Company’s on-going pivotal trial in ... Continue reading →

New Allon research presented at leading scientific symposium

VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) announced today that a presentation given May 12 at the prestigious 12th International Stockholm / Springfield Symposium on Advances in Alzheimer Therapy featured new research with Allon’s lead product candidate, davunetide, showing a preventio... Continue reading →

← Older posts Newer posts →